论文部分内容阅读
目的 为了探讨依普拉芬对绝经后骨质疏松的防治作用。 方法 以去势后雌性大鼠作实验模型 ,应用双能X线吸收骨密度测定 (DEXA)及光镜图像分析方法 ,观察依普拉芬对去势后雌性大鼠骨丢失的作用及单独、联合和交替使用雌激素、依普拉芬对椎骨、股骨骨密度的影响。 结果 依普拉芬与去势组间骨密度有显著性差异 (P <0 0 1) ,各用药组之间无显著性差异 ;光镜图像分析示去势组与依普拉芬组及其他各组间均有显著性差异。依普拉芬组与正常组间无显著性差异 ;依普拉芬组与联合应用或交替使用依普拉芬、雌激素组无显著性差异。 结论 单独用依普拉芬或雌激素能有效防止去势后大鼠的骨丢失 ;联合应用雌激素、依普拉芬不能增加疗效 ,交替使用亦可防止去势后大鼠的骨丢失
Objective To investigate the prevention and treatment of epoprufen on postmenopausal osteoporosis. Methods Female rats after ovariectomy were used as experimental models. The effects of Iprafin on bone loss in ovariectomized female rats were observed by dual energy X-ray absorptiometry (DEXA) and light microscope image analysis. Combined and alternating use of estrogen, Iprafin on vertebrae, femur bone mineral density. Results There was a significant difference in bone mineral density between Iprafen and Ovariectomized group (P <0.01), and no significant difference was found between the two groups. The light microscope image analysis showed that the castration group and Iprafen group and other There was significant difference among the groups. There was no significant difference between Iprafin group and normal group. There was no significant difference between Iprafin group and combined application or alternation of Iprafin and Estrogen group. Conclusion Iprafin alone or estrogen alone can effectively prevent bone loss after castration in rats; combination of estrogen and epiprofen can not increase the curative effect, and alternative use can prevent bone loss in castrated rats